Cardurion Pharmaceuticals Announces Appointment of Howard K. Surks, M.D., as Chief Scientific Officer and Head, Translational Medicine
Appointment reflects progress of Company’s early-stage pipeline toward the clinic BOSTON, Mass., December 14, 2020 – Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Howard K. Surks, M.D., as chief scientific officer […]
